Chalermchai Thep, Suwanrusme Harit, Chantranuwat Poonchavis, Voravud Narin, Sriuranpong Virote
Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Asia Pac J Clin Oncol. 2010 Jun;6(2):111-5. doi: 10.1111/j.1743-7563.2010.01284.x.
The aim of this study was to review cases of extra-pulmonary small cell carcinoma (EPSCC), including their clinical manifestations and treatment outcomes.
We retrospectively reviewed the medical records and pathological reports of patients who were diagnosed with EPSCC from 1998 to 2005.
Overall 21 EPSCC patients were eligible for this study. The most common primary sites were the gastrointestinal organs and the nasal cavity. Eleven patients (52.3%) had limited disease (LD) and 10 patients (47.7%) had extensive disease (ED). Nine patients underwent radical surgery alone, four received only radical radiation and two received only palliative chemotherapy. Two patients received adjuvant radiation or chemotherapy following surgical resection and one received a combination of all three treatment modalities. Three patients declined specific treatment and were treated with best supportive care. The median overall survival in the ED group was only 3 months (range 1-16 months), compared to 30 months (range 20-61 months) for LD. EPSCC of pancreas demonstrated a favorable clinical outcome with treatment, whereas primary EPSCC of the liver, esophagus and rectum had an aggressive natural history and a poor response to treatment.
Our report suggests that EPSCC may have a different biology from that of pulmonary small cell carcinoma. When detected at an early stage, EPSCC may have an excellent prognosis with treatment. Additional studies involving more patients with EPSCC are warranted to further define the optimal roles of each treatment modality.
本研究旨在回顾肺外小细胞癌(EPSCC)病例,包括其临床表现和治疗结果。
我们回顾性分析了1998年至2005年期间诊断为EPSCC患者的病历和病理报告。
共有21例EPSCC患者符合本研究条件。最常见的原发部位是胃肠道器官和鼻腔。11例患者(52.3%)为局限性疾病(LD),10例患者(47.7%)为广泛性疾病(ED)。9例患者仅接受了根治性手术,4例仅接受了根治性放疗,2例仅接受了姑息性化疗。2例患者在手术切除后接受了辅助放疗或化疗,1例接受了三种治疗方式的联合治疗。3例患者拒绝特定治疗,接受了最佳支持治疗。ED组的中位总生存期仅为3个月(范围1-16个月),而LD组为30个月(范围20-61个月)。胰腺EPSCC经治疗显示出良好的临床结果,而肝脏、食管和直肠的原发性EPSCC具有侵袭性的自然病程且对治疗反应不佳。
我们的报告表明,EPSCC可能具有与肺小细胞癌不同的生物学特性。早期发现时,EPSCC经治疗可能有良好的预后。需要更多涉及EPSCC患者的研究来进一步明确每种治疗方式的最佳作用。